Trials / Not Yet Recruiting
Not Yet RecruitingNCT07409454
MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
A Prospective, Single-Arm Clinical Trial of MRD-Guided BCMA/CD3 Bispecific Antibody as Maintenance Therapy After Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, single-arm clinical study designed to evaluate the efficacy and safety of the BCMA/CD3 bispecific antibody (CM336) as maintenance therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | anti-BCMA/CD3 bispecific antibody | Anti-BCMA/CD3 bispecific antibody (CM336) will be administered via a subcutaneous injection (SC). |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
- First posted
- 2026-02-13
- Last updated
- 2026-02-13
Source: ClinicalTrials.gov record NCT07409454. Inclusion in this directory is not an endorsement.